Literature DB >> 8023167

Rates of p16 (MTS1) mutations in primary tumors with 9p loss.

P Cairns, L Mao, A Merlo, D J Lee, D Schwab, Y Eby, K Tokino, P van der Riet, J E Blaugrund, D Sidransky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8023167     DOI： 10.1126/science.8023167

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  88 in total

Review 1.  The CDKN2A (p16) gene and human cancer.

Authors:  W D Foulkes; T Y Flanders; P M Pollock; N K Hayward
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

2.  The importance of clinical application of molecular biomarkers in bladder cancer detection.

Authors:  Raluca Dumache; Maria Puiu; Dana David; Marinela Popovici; Adriana Kaycsa; Serban Negru; Florin Miclea
Journal:  Maedica (Buchar)       Date:  2010-04

3.  P16 deletion and mutation analysis in human brain tumors.

Authors:  F G Barker; P Chen; F Furman; K D Aldape; M S Edwards; M A Israel
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

4.  Sample type bias in the analysis of cancer genomes.

Authors:  David A Solomon; Jung-Sik Kim; Habtom W Ressom; Zita Sibenaller; Timothy Ryken; Walter Jean; Darell Bigner; Hai Yan; Todd Waldman
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

5.  CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.

Authors:  P Schraml; K Struckmann; R Bednar; W Fu; T Gasser; K Wilber; J Kononen; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

6.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.

Authors:  Y E Whang; X Wu; H Suzuki; R E Reiter; C Tran; R L Vessella; J W Said; W B Isaacs; C L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

7.  Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas.

Authors:  V G Gorgoulis; E N Koutroumbi; A Kotsinas; P Zacharatos; C Markopoulos; L Giannikos; V Kyriakou; Z Voulgaris; I Gogas; C Kittas
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

8.  High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.

Authors:  A B Bianchi; S I Mitsunaga; J Q Cheng; W M Klein; S C Jhanwar; B Seizinger; N Kley; A J Klein-Szanto; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

Authors:  F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

Review 10.  Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis.

Authors:  V A Papadimitrakopoulou; D M Shin; W K Hong
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.